ClinicalTrials.gg
Enrolling by invitationNCT07586501Updated May 14, 2026

China-NINE Cohort:Neuroimmune Network in Elderly / Neurodegeneration

An observational study in Cognitive Dysfunction, Cognitive Dysfunction, Cognitive Disorder and Parkinson's Disease (PD), sponsored by Yantai Yuhuangding Hospital. Enrolling by invitation at 2 sites in China. Open to participants aged 55 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Yantai Yuhuangding Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
260
Ages
55 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 310 studies in Cognitive Dysfunction with a site in China — 144 open to participants now, 156 under way, 8 of them phase 3. Cognitive Dysfunction · China.

Planned enrollment
64th of 119
260 · median 300
Started
2026
with 44 others
Observational
119 of 310
64 open now
Primary completion
2029-01
later than 128 of 155 live
Registered
271st of 310
by date

Among the 310 studies in Cognitive Dysfunction with a site in China, this one is the 64th largest by planned enrollment of the 119 observational ones that give a count, is one of 45 that started in 2026, is one of 119 observational ones, reaches primary completion later than 128 of the 155 other live ones, and was the 271st registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

144 of the 310 studies in Cognitive Dysfunction with a site in China are open now. Recruiting first, the newest first:

139 more — sign in →

All 144 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 55 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 310 studies in Cognitive Dysfunction with a site in China, or all of them as a file.
02

Study summary

This is an observational study aimed at understanding the cognitive, functional, and behavioral characteristics of Chinese patients with cognitive impairment, exploring the underlying mechanisms, and providing evidence for early diagnosis, treatment, and care of cognitive disorders including dementia.

Eligible participants will undergo a series of assessments and examinations, including cognitive and memory scale tests, routine blood tests, ApoE genetic testing, cerebrospinal fluid testing, brain MRI, functional MRI, and FDG-PET/AV45-PET scans when necessary. Additional samples such as saliva, nasal secretions, and stool may also be collected. Most evaluations are provided free of charge to support diagnosis and treatment guidance.

Participation is voluntary. All personal information and research data will be kept confidential. Potential benefits include access to expert clinical care and free cognitive assessments for disease evaluation. Possible inconveniences include time commitment and temporary discomfort during examinations; medical support will be provided if needed.

03

Conditions studied

  • Cognitive Dysfunction
  • Cognitive Dysfunction, Cognitive Disorder
  • Parkinson's Disease (PD)

Keywords

  • Cognitive impairment, dementia, Alzheimer's disease, biomarker, brain MRI, neuroimaging, cognitive assessment, elderly population
  • Parkinson's disease
04

Who can participate

Ages eligible
55 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants were recruited from Yantai Yuhuangding Hospital, Yantai, Shandong Province, China.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with clinically diagnosed cognitive impairment. Patients with clinically diagnosed Parkinson's disease. Healthy control participants.

Exclusion criteria

Exclusion Criteria:

  • Central nervous system infection, head trauma, epilepsy, multiple sclerosis, or other major neurological disorders.

Malignant tumors. Family history of genetic disorders.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
260 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Degree and Type of Cognitive Impairment Assessed by Neuropsychological Scales

    Higher scores indicate better cognitive function; lower scores indicate more severe cognitive impairment.

    Time frame: From enrollment to the end of treatment at 3 years

07

Study locations

2 sites
08

References and documents

Publications

  • McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21. PubMed 21514250 ↗

Individual participant data

Plan to share: No — IPD will not be shared due to privacy regulations, ethical requirements, and limitations specified in the informed consent document.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2029, 35 months after the start.

Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 35 months is below that.

Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 14, 2026
StartActual
Jan 16, 2026
Primary completionEst.
Jan 1, 2029
CompletionEst.
Jan 1, 2029
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07586501
Lead sponsor
Yantai Yuhuangding Hospital
Responsible party
Maowen Ba (Chief Physician, Department of Neurology, Yantai Yuhuangding Hospital) — Principal investigator
First posted
May 14, 2026
Start date
Jan 16, 2026
Primary completion
Jan 1, 2029 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
May 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion